Good news regarding two of Groton-based Amarin Corp. PLC's patent applications pushed the company's stock price higher last week.
According to Amarin, the U.S. Patent & Trademark Office issued a notice this week that a patent was forthcoming because of "surprising and unexpected" findings during clinical trials of Vascepa, the company's heart pill.
Amarin's stock price soared from less than $14 a share early in the week to close to $15 shortly after the announcement. Shares settled at $14.78 Friday.
Amarin Chairman and chief executive Joseph Zakrzewski said the patents would be valid until at least 2030 once officially issued.
- Lee Howard